TY - JOUR
T1 - Can Stem Cells Restore Hearing? A Narrative Review Exploring Regenerative Medicine for Congenital Hearing Loss
AU - Mughal, Ainulakbar
AU - Amanullah, Fatima Syed
AU - Pasha, Hamdan Ahmed
AU - Kazmi, Syed Abbas Moazzam
AU - Vardag, Abdul Basit Shah
AU - Awan, Muhammad Sohail
N1 - Publisher Copyright:
© 2025 PLA General Hospital Department of Otolaryngology Head and Neck Surgery. Publishing services by Tsinghua University Press.
PY - 2025/10
Y1 - 2025/10
N2 - Introduction: Hearing loss, particularly congenital hearing loss, poses significant challenges to affected individuals and their families. Recent advancements in regenerative medicine have fueled interest in stem cell therapy as a potential solution for hearing restoration. This review discusses the feasibility of using stem cells to regenerate damaged cochlear structures and auditory neurons, focusing on their differentiation potential and integration into the cochlear environment. Discussion: Congenital hearing loss remains a significant global health challenge, with genetic mutations and syndromic conditions contributing to its high prevalence. Advances in regenerative medicine have led to increased interest in stem cell therapy as a potential solution for auditory restoration. Research on embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and mesenchymal stem cells (MSCs) has demonstrated their ability to differentiate into auditory cell types, offering a potential avenue for cochlear regeneration. Gene therapies also present a promising approach for addressing hereditary hearing loss by targeting specific genetic mutations. iPSCs in particular show promise, especially when combined with gene therapy for hereditary hearing loss. Despite encouraging preclinical findings, persistent hurdles remain: immune rejection, limited cell survival, difficulty with cochlear integration, and complex ethical and regulatory considerations. Addressing these barriers is crucial for safe and effective translation into clinical care. In Pakistan, there is a critical need to promote advancements in this field. Positioning Pakistan as an illustrative case within broader low-and middle-income country (LMIC) disparities underscores how limited infrastructure, funding gaps, and weak regulatory frameworks constrain progress and highlight opportunities for regional collaboration. Conclusion: As stem cell research advances, it is crucial to address ethical and regulatory considerations to ensure the responsible translation of these therapies into clinical practice. By integrating stem cell therapy with gene editing techniques and biomaterial scaffolding, the future of regenerative treatment for congenital hearing loss holds transformative potential.
AB - Introduction: Hearing loss, particularly congenital hearing loss, poses significant challenges to affected individuals and their families. Recent advancements in regenerative medicine have fueled interest in stem cell therapy as a potential solution for hearing restoration. This review discusses the feasibility of using stem cells to regenerate damaged cochlear structures and auditory neurons, focusing on their differentiation potential and integration into the cochlear environment. Discussion: Congenital hearing loss remains a significant global health challenge, with genetic mutations and syndromic conditions contributing to its high prevalence. Advances in regenerative medicine have led to increased interest in stem cell therapy as a potential solution for auditory restoration. Research on embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and mesenchymal stem cells (MSCs) has demonstrated their ability to differentiate into auditory cell types, offering a potential avenue for cochlear regeneration. Gene therapies also present a promising approach for addressing hereditary hearing loss by targeting specific genetic mutations. iPSCs in particular show promise, especially when combined with gene therapy for hereditary hearing loss. Despite encouraging preclinical findings, persistent hurdles remain: immune rejection, limited cell survival, difficulty with cochlear integration, and complex ethical and regulatory considerations. Addressing these barriers is crucial for safe and effective translation into clinical care. In Pakistan, there is a critical need to promote advancements in this field. Positioning Pakistan as an illustrative case within broader low-and middle-income country (LMIC) disparities underscores how limited infrastructure, funding gaps, and weak regulatory frameworks constrain progress and highlight opportunities for regional collaboration. Conclusion: As stem cell research advances, it is crucial to address ethical and regulatory considerations to ensure the responsible translation of these therapies into clinical practice. By integrating stem cell therapy with gene editing techniques and biomaterial scaffolding, the future of regenerative treatment for congenital hearing loss holds transformative potential.
KW - Embryonic Stem Cells
KW - Hearing loss
KW - Induced Pluripotent Stem Cells
KW - Mesenchymal Stem Cells
KW - Stem cells
UR - https://www.scopus.com/pages/publications/105021472921
U2 - 10.26599/JOTO.2025.9540039
DO - 10.26599/JOTO.2025.9540039
M3 - Review article
AN - SCOPUS:105021472921
SN - 1672-2930
VL - 20
SP - 253
EP - 258
JO - Journal of Otology
JF - Journal of Otology
IS - 4
ER -